Tenecteplase not associated with visual improvement in central retinal artery occlusion
1. In this randomized controlled trial of adults with central retinal artery occlusion, tenecteplase administration shortly after symptom onset did ...
1. In this randomized controlled trial of adults with central retinal artery occlusion, tenecteplase administration shortly after symptom onset did ...
AURN001 demonstrates improvement of visual acuity in patients with corneal endothelial dysfunction. The CLARA trial demonstrates favorable safety profiles across ...
Click here to read this article in JAMA Ophthalmology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in JAMA Ophthalmology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events ...
1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events ...
1. Avacincaptad pegol significantly slowed geographic atrophy over 12 months. 2. Exudative macular neovascularization was comparable among treatment groups. Evidence ...
1. In a small randomized controlled trial, children with amblyopia who used a newly developed binocular dichoptic home device had ...
1. In a large survey-based database, the percentage of children receiving vision screening decreased significantly from 69.6% to 60.1% between ...
1. In a phase 3a randomized trial comparing intravitreal brolucizumab to aflibercept for refractory neovascular age-related macular degeneration (nAMD), there ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.